Literature DB >> 26194552

Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.

Gerrit Frommeyer1, Lars Eckardt1.   

Abstract

Drug-induced ventricular tachyarrhythmias can be caused by cardiovascular drugs, noncardiovascular drugs, and even nonprescription agents. They can result in arrhythmic emergencies and sudden cardiac death. If a new arrhythmia or aggravation of an existing arrhythmia develops during therapy with a drug at a concentration usually considered not to be toxic, the situation can be defined as proarrhythmia. Various cardiovascular and noncardiovascular drugs can increase the occurrence of polymorphic ventricular tachycardia of the 'torsade de pointes' type. Antiarrhythmic drugs, antimicrobial agents, and antipsychotic and antidepressant drugs are the most important groups. Age, female sex, and structural heart disease are important risk factors for the occurrence of torsade de pointes. Genetic predisposition and individual pharmacodynamic and pharmacokinetic sensitivity also have important roles in the generation of arrhythmias. An increase in spatial or temporal dispersion of repolarization and a triangular action-potential configuration have been identified as crucial predictors of proarrhythmia in experimental models. These studies emphasized that sole consideration of the QT interval is not sufficient to assess the proarrhythmic risk. In this Review, we focus on important triggers of proarrhythmia and the underlying electrophysiological mechanisms that can enhance or prevent the development of torsade de pointes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26194552     DOI: 10.1038/nrcardio.2015.110

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  155 in total

1.  Drug Points: tachycardia associated with moxifloxacin.

Authors:  M Siepmann; W Kirch
Journal:  BMJ       Date:  2001-01-06

2.  Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.

Authors:  P B Iannini; S Doddamani; E Byazrova; I Curciumaru; H Kramer
Journal:  BMJ       Date:  2001-01-06

3.  Molecular analysis of potassium ion channel genes in sudden death cases among patients administered psychotropic drug therapy: are polymorphisms in LQT genes a potential risk factor?

Authors:  Sayako Kamei; Noriko Sato; Yuta Harayama; Miyako Nunotani; Kanae Takatsu; Tetsuya Shiozaki; Tokutaro Hayashi; Hideki Asamura
Journal:  J Hum Genet       Date:  2013-11-28       Impact factor: 3.172

4.  Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism.

Authors:  S Nattel; S Ranger; M Talajic; R Lemery; D Roy
Journal:  Am J Med       Date:  1990-08       Impact factor: 4.965

Review 5.  Pharmacology of antiarrhythmic drugs in elderly patients.

Authors:  William H Frishman; Wilbert S Aronow
Journal:  Clin Geriatr Med       Date:  2012-11       Impact factor: 3.076

6.  Torsades de pointe probably related to sparfloxacin.

Authors:  H Dupont; J F Timsit; B Souweine; B Gachot; M Wolff; B Regnier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

7.  OTc prolongation and torsade de pointes ventricular tachycardia in a small dose voriconazole therapy.

Authors:  M A Elbey; H Cil; E Onturk; Y Islamoglu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2012-01       Impact factor: 3.507

Review 8.  Animal models of ventricular arrhythmias.

Authors:  Robert L Hamlin
Journal:  Pharmacol Ther       Date:  2006-09-16       Impact factor: 12.310

9.  Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block.

Authors:  Peter Milberg; Shahram Ramtin; Gerold Mönnig; Nani Osada; Kristina Wasmer; Günter Breithardt; Wilhelm Haverkamp; Lars Eckardt
Journal:  J Cardiovasc Pharmacol       Date:  2004-09       Impact factor: 3.105

Review 10.  Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group.

Authors:  P Jaillon; J Morganroth; I Brumpt; G Talbot
Journal:  J Antimicrob Chemother       Date:  1996-05       Impact factor: 5.790

View more
  38 in total

Review 1.  Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies.

Authors:  Rezarta Cuni; Iris Parrini; Riccardo Asteggiano; Maria Rosa Conte
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

2.  Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice.

Authors:  Elisabetta Poluzzi; Emanuel Raschi; Igor Diemberger; Fabrizio De Ponti
Journal:  Drug Saf       Date:  2017-06       Impact factor: 5.606

3.  Risk of Cardiac Events Associated With Antidepressant Therapy in Patients With Long QT Syndrome.

Authors:  Meng Wang; Barbara Szepietowska; Bronislava Polonsky; Scott McNitt; Arthur J Moss; Wojciech Zareba; David S Auerbach
Journal:  Am J Cardiol       Date:  2017-11-13       Impact factor: 2.778

Review 4.  [Brugada syndrome : Risk stratification and prevention of sudden cardiac death].

Authors:  Lars Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2020-01-31

5.  Human ex-vivo action potential model for pro-arrhythmia risk assessment.

Authors:  Guy Page; Phachareeya Ratchada; Yannick Miron; Guido Steiner; Andre Ghetti; Paul E Miller; Jack A Reynolds; Ken Wang; Andrea Greiter-Wilke; Liudmila Polonchuk; Martin Traebert; Gary A Gintant; Najah Abi-Gerges
Journal:  J Pharmacol Toxicol Methods       Date:  2016-05-25       Impact factor: 1.950

Review 6.  [Updated ESC guideline: innovations for the treatment of ventricular arrhythmias and recommendations for prevention of sudden cardiac death].

Authors:  L Eckardt; T Deneke
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2016-09

Review 7.  Sex Differences in Human and Animal Toxicology.

Authors:  Michael Gochfeld
Journal:  Toxicol Pathol       Date:  2016-11-28       Impact factor: 1.902

8.  Investigating the Additive Interaction of QT-Prolonging Drugs in Older People Using Claims Data.

Authors:  Andreas D Meid; Anna von Medem; Dirk Heider; Jürgen-Bernhard Adler; Christian Günster; Hanna M Seidling; Renate Quinzler; Hans-Helmut König; Walter E Haefeli
Journal:  Drug Saf       Date:  2017-02       Impact factor: 5.606

9.  Risk of cardiac events in Long QT syndrome patients when taking antiseizure medications.

Authors:  David S Auerbach; Yitschak Biton; Bronislava Polonsky; Scott McNitt; Robert A Gross; Robert T Dirksen; Arthur J Moss
Journal:  Transl Res       Date:  2017-10-20       Impact factor: 7.012

Review 10.  [Ventricular tachyarrhythmia as a side effect of pharmacotherapy].

Authors:  Thomas Demming; Hendrik Bonnemeier
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.